AdAlta Ltd. (AU:1AD) has released an update.
AdAlta Ltd. has made significant strides in negotiating multiple term sheets for its AdSolis and AdCella units, securing a further $1 million from institutional investors New Life Sciences Capital LLC and Meurs Group. These funds will bolster the company’s efforts to bring AD-214, a novel treatment for fibrotic diseases, into Phase II clinical trials and to in-license advanced cellular immunotherapy products as part of its East to West strategy. Investors and stakeholders can anticipate updates on the company’s advancements, which promise to showcase the value of its i-body platform.
For further insights into AU:1AD stock, check out TipRanks’ Stock Analysis page.
